Publications by authors named "Alex Pokov"

Claim this Profile
C
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Victor L Serebruany, Ales Tomek, Alex N Pokov, Moo Hyun Kim

Expert Rev Cardiovasc Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
Victor L Serebruany, Alex N Pokov, Daniel Aradi, Mehmet Can, James DiNicolantonio

Am J Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge.
Victor L Serebruany, Alex N Pokov, Seth D Fortmann, James J DiNicolantonio

Thromb Haemost· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.
Victor L Serebruany, Michael Miller, Alex N Pokov, Donald Lynch, Jesper K Jensen

Cardiology· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans.
Charles H Hennekens, Wendy R Schneider, Alex Pokov, Scott Hetzel, David Demets

J Cardiovasc Pharmacol Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Victor L Serebruany, Alex I Malinin, Alex N Pokov, Daniel F Hanley

Clin Ther· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
Victor L Serebruany, Alex I Malinin, Alex Pokov, Gregory Barsness, Dan F Hanley

Am Heart J· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study.
Dan Atar, Alex Malinin, Alex Pokov, Louis van Zyl, Nancy Frasure-Smith

Neuropsychopharmacology· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Alex Malinin, Alex Pokov, Malcolm Spergling, Anthony Defranco, Kenneth Schwartz

Thromb Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Victor Serebruany, Alex Malinin, Alex Pokov, Umesh Arora, Dan Atar

Thromb Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study).
Victor L Serebruany, Michael Miller, Alex N Pokov, Alex I Malinin, David R Lowry

Am J Cardiol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
Victor Serebruany, Alex Malinin, Wendy Ziai, Dan Atar, Alex Pokov

Cerebrovasc Dis· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escitalopram, but not its major metabolites, exhibits antiplatelet activity in humans.
Dan Atar, Alex Malinin, Aviv Takserman, Alex Pokov, Louis van Zyl

J Clin Psychopharmacol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
Victor L Serebruany, Alex N Pokov, Alex I Malinin, Christopher O'Connor, Deepak L Bhatt

Am Heart J· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
Victor L Serebruany, Alex I Malinin, Wendy Ziai, Alex N Pokov, Deepak L Bhatt

Stroke· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis